Analyst Viewpoint
Heightened number of influenza cases is fostering a need for reliable medications to manage symptoms and offer long-term care to patients, a majority of whom may be kids or the elderly. This is augmenting influenza medication market size. Surge in healthcare expenses accompanied by productivity losses make affordable and effective treatment options a necessity. Thus, increase in research spending on influenza management drugs, especially post the COVID-19 pandemic, is driving market development.
Prominent players operating in the global influenza medication market are investing in R&D of novel drugs for relief or treatment of associated symptoms and illnesses. Leading players are also working on Influenza treatment options for pregnant women and people with compromised immune systems.
Influenza, commonly known as the flu, is an infectious disease caused by the influenza virus. It is highly contagious, causing severe illness and even death, especially among the people at high risk.
Pregnant women, people with compromised immune systems, and the geriatric population are the demographic that is at high risk of developing severe symptoms of influenza. Symptoms of the disease include cold, fever, cough, and sore throat, and can range from severe to mild. However, most people recover fully in a few days.
According to the World Health Organization (WHO), approximately 1 billion cases of seasonal influenza are recorded annually, with around 290,000 to 650,000 deaths caused by the virus. The influenza medication market is boosted by the production and application of seasonal vaccines and antiviral medicines.
Government efforts in raising awareness about the disease, its symptoms, and treatment is creating lucrative influenza medication market opportunities for companies operating in the industry. Constant innovations in cold and flu remedies are also augmenting market expansion.
Influenza virus spreads rapidly, making the disease highly contagious and prevalent among the population. Rise in prevalence of the disease has led to an urgent need for effective medications to manage symptoms and offer long-term care.
A characteristic of the virus is its tendency to undergo frequent genetic changes, forming newer strains that can counter antiviral treatments and challenge the immune system. According to the Centre for Disease Control and Prevention, around 200 pediatric deaths were recorded due to influenza across the U.S. during 2019–2020.
Surge in healthcare expenses, rise in hospitalizations, and productivity losses that accompany a severe influenza bout make effective and reliable treatment options a necessity, thus augmenting the influenza medication market growth.
Influenza virus is constantly evolving, creating a dynamic environment where ongoing research is required to identify new strains and enhance the efficiency of existing treatments. Research plays a vital role in the development of vaccines and antiviral remedies for influenza management. Thus, increase in spending on research and vaccine development is fostering expansion of the influenza medication industry.
Post-pandemic spending on research and development of treatment facilities and techniques to curb another viral outbreak has increased across the globe, as both government and corporations are weary of social and economic distress.
According to a report by the International Monetary Fund, R&D of a successful vaccine can range from US$ 200 Mn to 500 Mn, with manufacturing infrastructure at scale adding another half a billion at minimum.
According to the latest influenza medication market analysis, North America held the largest share of the global landscape in 2022. Surge in adoption of advanced drug therapies and increase in healthcare expenditure are augmenting the market dynamics of the region.
Growth in awareness campaigns is leading to a gradual decline in cases of influenza in Europe. However, the prevalence rate of the disease is still high. Therefore, the influenza medication market share of the region is high.
According to the latest influenza medication industry forecast, the industry in Asia Pacific is projected to grow at a steady pace from 2023 to 2031. Increase in cases of influenza, led by the presence of a vast percentage of population prone to infectious diseases in developing economies such as China and India, is boosting the influenza medication market demand in the region.
Prominent influenza medication manufacturers are investing significantly in the development of antigenic drift and shift medications to provide relief or treatment options for influenza. Several symptomatic relief pharmaceuticals and influenza management products are in different phases of clinical trials.
F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Mylan, Inc., GlaxoSmithKline plc, Daiichi Sankyo Company, and Natco Pharma are key companies operating in the global landscape.
The influenza medication market research report covers these key players in terms of parameters such as company overview, product portfolio, business strategies, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 907.0 Mn |
| Market Forecast Value in 2031 | US$ 1.1 Bn |
| Growth Rate (CAGR) | 2.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn/Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 907.0 Mn in 2022
It is projected to grow at a CAGR of 2.2% from 2023 to 2031
Need for reliable medications to manage symptoms and offer long-term care; and increase in spending on research and vaccine development
The oseltamivir product segment held the largest share in 2022
North America dominated the global landscape in 2022
F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Mylan, Inc., GlaxoSmithKline plc, Daiichi Sankyo Company, and Natco Pharma
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Influenza Medication Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Influenza Medication Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Zanamivir
6.3.2. Oseltamivir
6.3.3. Peramivir
6.3.4. Amantadine
6.3.5. Rimantadine
6.3.6. Inosine
6.3.7. Others (Laninamivir Octanoate, etc.)
6.4. Market Attractiveness, by Product Type
7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Pharmacies
7.3.4. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Influenza Medication Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Influenza Medication Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2017–2031
9.2.1. Zanamivir
9.2.2. Oseltamivir
9.2.3. Peramivir
9.2.4. Amantadine
9.2.5. Rimantadine
9.2.6. Inosine
9.2.7. Others (Laninamivir Octanoate, etc.)
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Pharmacies
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Influenza Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017–2031
10.2.1. Zanamivir
10.2.2. Oseltamivir
10.2.3. Peramivir
10.2.4. Amantadine
10.2.5. Rimantadine
10.2.6. Inosine
10.2.7. Others (Laninamivir Octanoate, etc.)
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Pharmacies
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Influenza Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Zanamivir
11.2.2. Oseltamivir
11.2.3. Peramivir
11.2.4. Amantadine
11.2.5. Rimantadine
11.2.6. Inosine
11.2.7. Others (Laninamivir Octanoate, etc.)
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Pharmacies
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Influenza Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Zanamivir
12.2.2. Oseltamivir
12.2.3. Peramivir
12.2.4. Amantadine
12.2.5. Rimantadine
12.2.6. Inosine
12.2.7. Others (Laninamivir Octanoate, etc.)
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Pharmacies
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Influenza Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Zanamivir
13.2.2. Oseltamivir
13.2.3. Peramivir
13.2.4. Amantadine
13.2.5. Rimantadine
13.2.6. Inosine
13.2.7. Others (Laninamivir Octanoate, etc.)
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Pharmacies
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.,
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Teva Pharmaceutical Industries Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Sandoz International GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sun Pharmaceutical Industries Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Mylan, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. GlaxoSmithKline plc
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Daiichi Sankyo Company
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Natco Pharma
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
List of Tables
Table 01: Global Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Influenza Medication Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 05: North America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: North America Influenza Medication Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 08: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 11: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 14: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 17: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031
Figure 02: Global Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 03: Global Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 04: Global Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 05: Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 06: Global Influenza Medication Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Influenza Medication Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031
Figure 09: North America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 10: North America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 11: North America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 12: North America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 13: North America Influenza Medication Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Influenza Medication Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031
Figure 16: Europe Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 17: Europe Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 18: Europe Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 19: Europe Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 20: Europe Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031
Figure 23: Asia Pacific Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 24: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 25: Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 26: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Asia Pacific Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031
Figure 30: Latin America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 31: Latin America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 32: Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Latin America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 34: Latin America Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031
Figure 37: Middle East & Africa Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 38: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 39: Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 41: Middle East & Africa Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Influenza Medication Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Influenza Medication Market
